Vanda Pharmaceuticals Inc.

LSE:0LKB Stock Report

Market Cap: US$278.7m

Vanda Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Vanda Pharmaceuticals's earnings have been declining at an average annual rate of -65.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 3.9% per year.

Key information

-65.6%

Earnings growth rate

-66.5%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate-3.9%
Return on equity-3.0%
Net Margin-8.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vanda Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0LKB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24191-1613179
30 Jun 24182-1111879
31 Mar 24178-510779
31 Dec 23193311377
30 Sep 232121212271
30 Jun 232381512779
31 Mar 232571613284
31 Dec 22254613686
30 Sep 22258613787
30 Jun 222631114081
31 Mar 222661813580
31 Dec 212693312475
30 Sep 212683412671
30 Jun 212593212864
31 Mar 212533213356
31 Dec 202482314156
30 Sep 202411914254
30 Jun 2024111413853
31 Mar 2023711713651
31 Dec 1922711613049
30 Sep 1921912211848
30 Jun 192092811349
31 Mar 191972211047
31 Dec 181932510644
30 Sep 181841311241
30 Jun 18177111740
31 Mar 18171-512037
31 Dec 17165-1612439
30 Sep 17159-1411736
30 Jun 17156-1010733
31 Mar 17150-1310132
31 Dec 16146-1810029
30 Sep 16140-3210530
30 Jun 16129-4110133
31 Mar 16121-429532
31 Dec 15110-408529
30 Sep 1593457325
30 Jun 1580536619
31 Mar 1563367616
31 Dec 1450208519
30 Sep 1444-577721
30 Jun 1437-617225
31 Mar 1435-434928
31 Dec 1334-212529

Quality Earnings: 0LKB is currently unprofitable.

Growing Profit Margin: 0LKB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0LKB is unprofitable, and losses have increased over the past 5 years at a rate of 65.6% per year.

Accelerating Growth: Unable to compare 0LKB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0LKB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 0LKB has a negative Return on Equity (-3.03%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:51
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vanda Pharmaceuticals Inc. is covered by 21 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
null nullArgus Research Company
Olivia BrayerBofA Global Research